Shugan Heluo Xingpi Decoction inhibits liver fibrosis through regulation of Wnt/β-Catenin signaling pathway

Kuisong WANG; Qiuju ZHANG; Shuyao WEI; Shipeng YIN; Jieyu LI; Shiyu CHEN; Jiaqi GUO; Kunpeng ZHAO

doi:10.3969/j.issn.1001-5256.2022.10.013

Volume 38 Issue 10

Oct. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(10): 2265-2272

PDF( 4203 KB)

Shugan Heluo Xingpi Decoction inhibits liver fibrosis through regulation of Wnt/β-Catenin signaling pathway

DOI: 10.3969/j.issn.1001-5256.2022.10.013

a.
School of Clinical Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
b.
School of Basic Medicine, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
c.
School of Public Health, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China
d.
Department of Ancient Books of Library, Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China

Research funding:

National Natural Science Foundation of China (81660772);

Innovation Fund Project of Gansu Higher Education Institutions (2020A-074);

Scientific Research Innovation Fund of Gansu University of Traditional Chinese Medicine (2018-03)

More Information

Corresponding author: ZHAO Kunpeng, 896100698@qq.com(ORCID: 0000-0003-0556-1600)
Received Date: 2022-03-25
Accepted Date: 2022-05-19
Published Date: 2022-10-20

Abstract

Abstract

Objective To investigate the therapeutic effect of Shugan Heluo Xingpi Decoction on CCl₄-induced liver fibrosis in rats, and the underlying molecular mechanism. Methods Sixty male SPF Wistar rats were randomly assigned to six groups: blank control, model, positive control, high, medium or low dose groups of Shugan Heluo Xingpi Decoction (n=10 per group). The liver fibrosis rat model was induced by an intraperitoneal injection of 40% CCl₄ oil solution. Rats in the blank control and model groups were administered 10 mL/kg normal saline by gavage, rats in the positive control group were administered 50 mg/kg silibinin meglumine by gavage, while rats in high-dose, medium-dose and low-dose groups of Shugan Heluo Xingpi Decoction were administered 12.42 g/kg, 6.21 g/kg and 3.11 g/kg (crude drug/body weight) by gavage, respectively, daily for 8 weeks. Rats was sacrificed after 8 weeks, during which the physiological status of rats in each group was dynamically monitored. Following sacrifice, serum was collected to detect HYP using alkaline hydrolysis colorimetry and the expression levels of AST, ALT, total protein (TP), and Alb using an automatic biochemical analyzer. The pathological morphological changes in the liver were detected by H & E staining and Masson staining, and the mRNA and protein levels of Wnt1, β-Catenin and Cyclin D1 were detected by RT-qPCR and Western Blot. Measurement data were compared across groups using one-way ANOVA with post-hoc LSD-t test. Results Compared with the model group, after silibinin meglumine and Shugan Heluo Xingpi Decoction intervention, the physiological status of rats was significantly improved; serum levels of HYP, ALT, AST and Glo were significantly decreased, while serum levels of TP, Alb and A/G were significantly increased (all P < 0.05). Compared with the positive control group, serum levels of ALT and AST were significantly increased (all P < 0.05), while the levels of TP, Alb and A/G were significantly decreased (all P < 0.05) in low-dose group of Shugan Heluo Xingpi Decoction. H&E staining showed mild portal vein fibrosis with a few fibrous septa and mild steatosis of hepatocytes in the positive control group, obvious portal vein fibrosis with a few fiber septum in the low dose group, a few portal vein fibrosis in the medium dose group, while no obvious abnormality in the high dose group of Shugan Heluo Xingpi Decoction. Masson staining revealed that the therapeutic effect of high dose group of Shugan Heluo Xingpi Decoction on collagen deposition was superior to silibinin meglumine and medium and low dose of Shugan Heluo Xingpi Decoction (all P < 0.05), and was generally equivalent to high dose of Shugan Heluo Xingpi Decoction. Silibinin meglumine and medium and high doses of Shugan Heluo Xingpi Decoction inhibited more significantly the mRNA and protein expression of Wnt1, β-catenin and Cyclin D1 (all P < 0.05). Conclusion Shugan Heluo Xingpi Decoction shows anti-hepatic fibrosis effect, with a greater effect at higher doses. Regulating Wnt/β-Catenin signaling pathway may be one of the underlying molecular mechanisms.
- Liver Cirrhosis,
- Wnt Signaling Pathway,
- Shugan Heluo Xingpi Decoction

FullText(HTML)

References(17)

References

[1]	LU LG, YOU H, XIE WF, et al. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007. 陆伦根, 尤红, 谢渭芬, 等. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35(10): 2163-2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
[2]	ZHOU XY. The medical essence of national TCM master Zhou Xin[M]. China Pharmaceutical Science and Technology Press, 2017. 周信有. 国医大师周信有医学精华[M]. 中国医药科技出版社, 2017.
[3]	NISHIKAWA K, OSAWA Y, KIMURA K. Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs[J]. Int J Mol Sci, 2018, 19(10): 3103. DOI: 10.3390/ijms19103103.
[4]	ZHANG QJ, WANG KS, SUN MH, et al. Effect of water extraction and alcohol extraction on anti-hepatic fibrosis of Shugan Heluo Xingpi decoction[J]. Tradit Chin Med Res, 2021, 34(11): 52-56. DOI: 10.3969/j.issn.1001-6910.2021.11.15. 张秋菊, 王奎淞, 孙墨晗, 等. 水提法和醇提法对舒肝和络醒脾方抗肝纤维化作用的影响[J]. 中医研究, 2021, 34(11): 52-56. DOI: 10.3969/j.issn.1001-6910.2021.11.15.
[5]	LIU YQ, LIU M, LIU YX, et al. Analysis of the application of randomization methods in clinical trials in NEJM[J]. Chin J Evid-based Med, 2021, 21(3): 303-307. DOI: 10.7507/1672-2531.202010080. 刘雅琦, 刘曼, 刘玉秀, 等. 《新英格兰医学杂志》临床试验随机化方法应用状况评价[J]. 中国循证医学杂志, 2021, 21(3): 303-307. DOI: 10.7507/1672-2531.202010080.
[6]	WANG KS, ZHAO KP, ZHANG QJ. Progress in experimental animal models of liver fibrosis[J]. Med & Pharm J Chin PLA, 2021, 33(11): 113-116. DOI: 10.3969/j.issn.2095-140X.2021.11.028. 王奎淞, 赵鲲鹏, 张秋菊. 常用肝纤维化实验动物模型研究进展[J]. 解放军医药杂志, 2021, 33(11): 113-116. DOI: 10.3969/j.issn.2095-140X.2021.11.028.
[7]	DONG YS. Modification of liver fibrosis composite model and its histopathological evaluation[J/CD]. Electronic J Clin Med Lit, 2018, 5(5): 10-11. DOI: 10.3877/j.issn.2095-8242.2018.05.007. 董永胜. 肝脏纤维化复合模型的改良及病理组织学评价[J/CD]. 临床医药文献电子杂志, 2018, 5(5): 10-11. DOI: 10.3877/j.issn.2095-8242.2018.05.007.
[8]	WEI W. Methodology of pharmacological experiment[M]. People's Health Publishing House, 2010. 魏伟. 药理实验方法学[M]. 人民卫生出版社, 2010.
[9]	WANG WT, LI Y, HUANG T, et al. Diagnostic value of semi-quantitative analysis of microscopic images of masson's trichrome-stained histological sections in renal interstitial fibrosis[J]. Chin Gen Pract, 2020, 23(33): 4202-4208. DOI: 10.12114/j.issn.1007-9572.2020.00.394. 王文涛, 李燕, 黄婷, 等. Masson染色联合图像半定量分析对肾间质纤维化的诊断及评价研究[J]. 中国全科医学, 2020, 23(33): 4202-4208. DOI: 10.12114/j.issn.1007-9572.2020.00.394.
[10]	LI Q, TENG L, LI YQ, et al. ZHOU Xinyou's experience in treating viral cirrhosis[J]. J Tradit Chin Med, 2018, 59(8): 643-645. DOI: 10.13288/j.11-2166/r.2018.08.004. 李琼, 滕龙, 李永勤, 等. 周信有辨治病毒性肝硬化经验[J]. 中医杂志, 2018, 59(8): 643-645. DOI: 10.13288/j.11-2166/r.2018.08.004.
[11]	YIN SP. The clinical effective prescription record of national TCM master Zhou Xin[M]. People's Health Publishing House, 2021. 殷世鹏. 国医大师周信有临证效验方录[M]. 人民卫生出版社, 2021.
[12]	ZHANG Y, LI JT. Professor Zhou Xinyou's clinical thinking and experience in treating hepatitis B[J]. Yunnan J Tradit Chin Med Mater Med, 2006, 27(6): 4. DOI: 10.3969/j.issn.1007-2349.2006.06.003. 张毅, 李金田. 周信有教授辨治乙型肝炎的临证思路与经验[J]. 云南中医中药杂志, 2006, 27(6): 4. DOI: 10.3969/j.issn.1007-2349.2006.06.003.
[13]	YANG J, QU J, CHEN LM. Academic thought and clinical experience of national TCM master Zhou Xinyou in treating chronic viral hepatitis B[J]. Chin J Inf Tradit Chin Med, 2021, 28(8): 118-120. DOI: 10.19879/j.cnki.1005-5304.202005084. 杨军, 屈杰, 陈丽名. 国医大师周信有论治慢性乙型病毒性肝炎学术思想和临证经验[J]. 中国中医药信息杂志, 2021, 28(8): 118-120. DOI: 10.19879/j.cnki.1005-5304.202005084.
[14]	MIAO CG, YANG YY, HE X, et al. Wnt signaling in liver fibrosis: progress, challenges and potential directions[J]. Biochimie, 2013, 95(12): 2326-2335. DOI: 10.1016/j.biochi.2013.09.003.
[15]	SUN HT. The molecular mechanism of P65 regulating HSCs activation through Wnt signaling pathway and the intervention effect of turtle shell oligopeptide I-C-F-6[D]. Guangzhou: Southern Medical University, 2018. 孙海涛. NF-κB P65通过Wnt信号通路调控HSCs活化的分子机制及鳖甲寡肽I-C-F-6的干预作用[D]. 广州: 南方医科大学, 2018.
[16]	LI LY. Effects of Sini Ruangan Decoction on P53 and CyclinD 1 in hepatic stellate cells[D]. Changsha: Hunan University of Chinese Medicine, 2019. 李凌云. 四逆软肝方对肝星状细胞P53、CyclinD 1因子的影响[D]. 长沙: 湖南中医药大学, 2019.
[17]	DAI Q, LUO YB, LI MQ, et al. Yiqi Huoxue Lishui decoction inhibited the Wnt/β-catenin signaling pathway in the liver of rats with chronic hepatic fibrosis[J]. Genomics Appl Biol, 2018, 37(4): 1697-1704. DOI: 10.13417/j.gab.037.001697. 戴琦, 罗勇兵, 李梦乔, 等. 益气活血利水汤抑制慢性肝纤维化大鼠肝脏Wnt/β-catenin信号通路[J]. 基因组学与应用生物学, 2018, 37(4): 1697-1704. DOI: 10.13417/j.gab.037.001697.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(3) / Tables(8)

Get Citation

PDF

XML

Article Metrics

Article views (324) PDF downloads(41)

Shugan Heluo Xingpi Decoction inhibits liver fibrosis through regulation of Wnt/β-Catenin signaling pathway

DOI: 10.3969/j.issn.1001-5256.2022.10.013

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Shugan Heluo Xingpi Decoction inhibits liver fibrosis through regulation of Wnt/β-Catenin signaling pathway

DOI: 10.3969/j.issn.1001-5256.2022.10.013

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content